MEK inhibitors for the treatment of NRAS mutant melanoma
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is increasing rapidly in incidence and prevalence, espec...
Saved in:
Main Authors: | Sarkisian S (Author), Davar D (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022) -
NRAS mutant melanoma arising in a giant congenital melanocytic nevus in an infant
by: Neha Bansal, et al.
Published: (2021) -
Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report
by: Jiri Vachtenheim, et al.
Published: (2020) -
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
by: Tran KA, et al.
Published: (2015) -
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
by: Juanjuan Feng, et al.
Published: (2023)